Cagrilintide FDA status: trials, CagriSema, and compounding claims

01

Current approval status

FDA's June 2026 page on unapproved GLP-1 drugs states that cagrilintide is not a component of an FDA-approved drug and has not been found safe and effective for any condition. A search result, trial registry entry, peer-reviewed paper, company announcement, or FDA substance identifier does not change that status.

Approval is determined through an approved application and current labeling for a defined product. If a provider says cagrilintide is approved, ask for the brand name, application record, label, manufacturer, and approved use. A vague reference to FDA registration, a UNII, an NDC, or “pharmaceutical grade” is not an approval record.

02

What cagrilintide and CagriSema research studies

Cagrilintide is a long-acting analogue of amylin, a hormone involved in satiety. Some trials study cagrilintide alone; others study it with semaglutide under the development name CagriSema. Results for the combination cannot be assigned to cagrilintide alone, and results for a sponsor's defined investigational product cannot validate a separately manufactured blend.

The phase 2 cagrilintide study indexed in PubMed enrolled adults with overweight or obesity and compared several investigational doses with placebo and liraglutide over 26 weeks. Later CagriSema trials use different designs, populations, durations, comparators, and outcomes. Those distinctions matter when a marketing page cites a percentage without explaining which product and trial produced it.

03

How to read the current Phase 3 record

ClinicalTrials.gov lists REDEFINE 3 as a Phase 3 cardiovascular-outcomes study of CagriSema in people with cardiovascular disease and overweight or obesity. The record was updated July 17, 2026, lists the study as active but not recruiting, and gives an estimated primary completion in 2027. It does not post results.

A Phase 3 designation describes a development stage, not a finding that the product works or is approved. “Active, not recruiting” means the study continues without enrolling new participants; it does not mean FDA has accepted an application. Estimated completion dates can change, and a registry's sponsor-provided information should be rechecked.

04

FDA's compounding statement is explicit

FDA's current consumer page says retatrutide and cagrilintide cannot be used in compounding under federal law. The same page says they are not components of approved drugs and have not been found safe and effective for any condition. This is more specific than the general rule that some compounded drugs may meet patient needs in limited circumstances.

A pharmacy license, 503A description, or 503B registration does not override ingredient eligibility rules. Nor does a prescriber's order transform an ineligible bulk substance into an approved drug. If a clinic markets “compounded cagrilintide,” preserve the exact wording, identify every entity involved, and compare the claim with the current FDA page and applicable regulatory records.

05

Online and research-use claims

FDA's 2024 warning letter to Xcel Research described cagrilintide and a cagrilintide-semaglutide blend sold with human-use claims despite research-only wording. FDA treated the products named in that letter as unapproved new drugs based on intended-use evidence. The letter applies to its recipient and facts; it is not proof that every seller has identical conduct.

The broader lesson is that disclaimers do not erase the overall message of a product page. Dosing instructions, body-weight promises, disease language, testimonials, and human-use directions can show intended use. Consumers should not purchase injectable research products for self-administration, and should not infer identity, sterility, potency, or safety from a certificate alone.

06

A verification checklist for provider claims

Record the exact ingredient, whether it is cagrilintide alone or a combination, the route, the claimed purpose, the seller, the prescribing clinician, and the dispensing source. Ask the provider to classify the product as approved, off-label, compounded, investigational, or otherwise unapproved and to identify the source supporting that classification.

Check FDA's current status page and Drugs@FDA, then match any study citation by trial identifier. Verify clinician and pharmacy licenses independently. Do not interpret this research as a treatment recommendation; questions about weight management or metabolic disease belong with an appropriately licensed clinician who can discuss approved options and individual risks.

• →Exact ingredient and combination
• →Approval or investigational record
• →Trial identifier and posted-results status
• →Prescriber and pharmacy identity
• →Source date and current FDA wording